Mutated JAK kinases and deregulated STAT activity are potential therapeutic targets in cutaneous T cell lymphoma

Disclosures: All authors declare no conflict of interest except MAP. MAP has the following conflicts of interest: Takeda-advisory board. Novartis, Amgen and Roche: Speaker bureau.

Contributions: JPV, MAP, POR and MSB designed and supervised the work. CP, JPV, MAP, MSB and POR wrote the manuscript. CP, JGR, CA, NGD, HP, SCO, SG and RM performed experiments. JPV, CP, JGR, MSB, NM and MAP analyzed data. AO, LC, MH, DSM, JLRP, CP, ALC, CGV, POR and MAP followed up, characterized and selected patients and collected, classified and handled clinical samples.